Sign In

Andrew Schiermeier

Chief Operating Officer at Intellia Therapeutics, Inc.

Professional Background

Andrew Schiermeier is a distinguished leader in the biopharmaceutical industry, currently serving as the Chief Operating Officer at Intellia Therapeutics, Inc. His extensive experience spans various leadership roles that have significantly influenced corporate strategy, development, and research at Intellia Therapeutics. Previously, he served as the Executive Vice President at the same company, where he also held the role of interim Head of Research. Andrew has a rich history in oncology and immuno-oncology, having worked as the Senior Vice President and Global Head of Oncology for the Pfizer/Merck ImmunoOncology Alliance at Merck KGaA, in Darmstadt, Germany.

His career trajectory showcases a blend of operational management, strategic oversight, and advisory expertise. Andrew has also held leadership positions at Aura BioSciences, where he was the Chief Operating Officer, and at Lantibio, Inc., where he served as CEO. His impressive resume further includes roles at prominent firms such as Ernst & Young and Aventis Pharma, where he honed his skills in strategic decision-making and corporate advisement.

Education and Achievements

Andrew Schiermeier's educational background underscores his dedication to excellence in engineering and business. He holds a Bachelor of Science in Engineering from the prestigious University of Cambridge. He further pursued a dual Bachelor of Science in Mechanical Engineering from Washington University in St. Louis, solidifying his technical expertise.

Demonstrating a commitment to further advancing his knowledge, Andrew obtained his Master of Science in BioMechanics and Engineering from Stanford University, followed by a Ph.D. in Engineering and Applied Math from Harvard University. Most recently, he studied for an MBA in Finance and Strategy at the College des Ingenieurs, equipping him with vital skills needed to navigate the complexities of the business aspects of technology and health sciences.

Significant Leadership Roles

Throughout his career, Andrew has undertaken several significant leadership positions that exemplify his capability to merge science with strategic business acumen. As the Chief Operating Officer at Intellia Therapeutics, he has been at the forefront of innovative developments in the field of genome editing and biotherapies. His previous role as Executive Vice President allowed him to contribute to corporate strategy while overseeing vital research initiatives that align with company goals.

Andrew's tenure at Merck KGaA allowed him to lead the Global Head of Oncology division, where he was instrumental in crafting and executing strategies that delivered impactful therapeutic options to patients worldwide.

His commitment to innovation is also reflected in his previous positions at Aura BioSciences and Lantibio, where he emphasized the need for advanced therapies and operational excellence. He possesses deep insights into the industry's needs, driven by both his academic background and hands-on leadership experience.

In addition, Andrew has served as a Corporate Advisor at Pathogenica, Inc., where his broad knowledge of biotechnology and corporate strategy informed critical decisions during the company's growth phase. He has led teams through significant transitions and has consistently aligned operational efforts with strategic objectives across multiple organizations.

Community Engagement and Advisory Roles

In a commitment to giving back to the community and advancing the field of medicine, Andrew has held notable positions such as Chairman and former CEO of Medicine in Need (MEND). His leadership in organizations that emphasize health education, disease prevention, and resource accessibility signifies his dedication to improving global health.

As a seasoned executive, he values mentorship and driving innovation within the industry. His participation in various committees and organizations highlights his commitment to the advancement of both science and society, bridging the gap between medical research and practical application.

Conclusion

Andrew Schiermeier’s exceptional blend of educational qualifications and extensive experience in high-level corporate roles within the biopharmaceutical sphere positions him as a key figure in advancing medicine through strategic innovation and research. His leadership at Intellia Therapeutics continues to set benchmarks in an industry that is rapidly evolving, while his commitment to education and community service reflects his holistic approach to healthcare and bioengineering.

Related Questions

How did Andrew Schiermeier's academic background influence his career in the biopharmaceutical industry?
What strategies has Andrew Schiermeier implemented at Intellia Therapeutics to drive innovation?
In what ways has Andrew Schiermeier contributed to the field of oncology during his time at Merck KGaA?
What are Andrew Schiermeier's future goals for the biopharmaceutical sector?
How does Andrew Schiermeier's experience in engineering enhance his strategic decision-making in healthcare?
Andrew Schiermeier
Add to my network

Location

Cambridge, Massachusetts, United States